Purpose: Physicians in the United States report fewer than 1% of adverse drug events (ADEs) to the Food and Drug Administration (FDA), but frequently document ADEs within electronic health records (EHRs). We developed and implemented a generalizable, scalable EHR-based system to automatically send electronic ADE reports to the FDA in real-time.

Methods: Proof-of-concept study involving 26 clinicians given access to EHR-based ADE reporting functionality from December 2008 to May 2009.

Measurements: Number and content of ADE reports; severity of adverse reactions (clinician and computer algorithm defined); clinician survey.

Results: During the study period, 26 clinicians submitted 217 reports to the FDA. The clinicians defined 23% of the ADEs as serious and a computer algorithm defined 4% of the ADEs as serious. The most common drug classes were cardiovascular drugs (40%), central nervous system drugs (19%), analgesics (13%), and endocrine drugs (7%). The reports contained information, pre-filled from the EHR, about comorbid conditions (207 reports [95%] listed 1899 comorbid conditions), concurrent medications (193 reports [89%] listed 1687 concurrent medications), weight (209 reports [96%]), and laboratory data (215 reports [99%]). It took clinicians a mean of 53 seconds to complete and send the form. In the clinician survey, 21 of 23 respondents (91%) said they had submitted zero ADE reports to the FDA in the prior 12 months.

Conclusions: EHR-based, triggered ADE reporting is efficient and acceptable to clinicians, provides detailed clinical information, and has the potential to greatly increase the number and quality of spontaneous reports submitted to the FDA.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pds.2027DOI Listing

Publication Analysis

Top Keywords

ade reports
12
reports fda
12
reports
10
electronic health
8
adverse drug
8
ade reporting
8
computer algorithm
8
algorithm defined
8
ades serious
8
comorbid conditions
8

Similar Publications

Using multiple drug similarity networks to promote adverse drug event detection.

Heliyon

November 2024

Department of Computer Science and Engineering, The Ohio State University, 2015 Neil Ave, Columbus, OH 43210, USA.

The occurrence of an adverse drug event (ADE) has become a serious social concern of public health. Early detection of ADEs can lower the risk of drug safety as well as the expense of the drug. While post-market spontaneous reports of ADEs remain a cornerstone of pharmacovigilance, most existing signal detection algorithms rely on substantial accumulated data, limiting their applicability to early ADE detection when reports are scarce.

View Article and Find Full Text PDF

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.

PLoS One

December 2024

The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety. Based on the FDA adverse event reporting system (FAERS) database, this study aims to mine the adverse reaction signals of the latest major recommended drug Nirmatrelvir/Ritonavir for the antiviral treatment of COVID-19, so as to provide a basis for safe and rational drug use.

View Article and Find Full Text PDF

Background: With the clinical integration of sugammadex, a selective relaxant-binding agent, the approach to reversing neuromuscular blockade is revolutionized. Despite its efficacy, sugammadex's adverse reactions range from mild symptoms to severe cases, including anaphylaxis and coagulopathy. Assessing the nature of these reactions using the Food and Drug Administration's Adverse Event Reporting System (FAERS) database is vital for safe anesthetic practice.

View Article and Find Full Text PDF

The carbonyl nucleobase adduct MAde is a potent antigen for adaptive polyclonal MR1-restricted T cells.

Immunity

December 2024

Experimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland. Electronic address:

The major histocompatibility complex (MHC) class I-related molecule MHC-class-I-related protein 1 (MR1) presents metabolites to distinct MR1-restricted T cell subsets, including mucosal-associated invariant T (MAIT) and MR1T cells. However, self-reactive MR1T cells and the nature of recognized antigens remain underexplored. Here, we report a cell endogenous carbonyl adduct of adenine (8-(9H-purin-6-yl)-2-oxa-8-azabicyclo[3.

View Article and Find Full Text PDF

We obtained the photoelectron spectra of Rh(CN) using the negative ion photoelectron velocity-map imaging (NI-PEVMI) technique and revealed the photodesorption process of Rh(CN). The vertical detachment energy (VDE) and adiabatic detachment energy (ADE) of Rh(CN) have both been experimentally reported to be 2.04 (3) eV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!